Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a corporate update. It entered a global Roche collaboration for bexobrutideg (NX-5948) with up to $2.3B total payments, including a $700M upfront. Nurix said EHA data showed CLL/SLL ORR of 83% (PFS 22.1 months) and cash of $443.5M as of May 31, 2026.
How this was made
The 30-second read
Why it matters
The Roche agreement provides substantial non-dilutive funding (expected $700M upfront) and expands development into immunology and neurology, while the company also reiterates CLL registrational trial progress and reports updated CLL/SLL response metrics.
Market read
Traders can reassess NRIX’s near-term funding runway and probability-weighted value of bexobrutideg after a large upfront partnership and expanded indication plan.
What to watch
Roche cost share and profit/loss mechanics (US equal sharing, ex-US royalties) can cap upside versus full ownership; dilution risk is not assessed here beyond cash/pro-forma figures.
Background
Nurix is a clinical-stage targeted protein degradation company; this update combines Q2 financials with a new Roche collaboration for its BTK degrader bexobrutideg (NX-5948).
Ticker impact
Nurix entered a global Roche collaboration for bexobrutideg (NX-5948) with a $700M upfront payment and up to $2.3B total potential.
Near-term upside bias on deal closing expectations and improved risk profile; magnitude depends on market appetite for biotech partnership risk.
The article discloses a large upfront ($700M), defined cost-sharing (40%/60%), and concrete clinical expansion plans (MS, CSU) plus ongoing CLL registrational milestones.
Market effects
Reinforces continued pharma interest in BTK degraders and targeted protein degradation platforms, potentially improving sentiment for adjacent degrader developers.
Limited direct regional impact beyond US-listed biotech investor flows.
Roche partnership is global and includes ex-US royalties, which can influence international biotech partnership expectations.
Counterpoint
Upfront is contingent on closing conditions and milestones are not guaranteed; clinical outcomes in MS/CSU and CLL still drive long-term value.
Key entities
- public_companyNurix Therapeutics, Inc.
Nasdaq-listed targeted protein degradation biopharma; subject of the financial results and Roche collaboration update.
- public_companyRoche
Global pharma partner entering a co-development and co-commercialization collaboration for bexobrutideg.
- product_candidatebexobrutideg (NX-5948)
Nurix BTK degrader central to the Roche collaboration and ongoing CLL program.
